Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02112045 · ClinicalTrials.gov registry record · Phase 2
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT02112045 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 90 participants.
The verdict
NCT02112045, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This randomized phase II trial compares how well adding XMO2 Filgrastim (Granix) to melphalan before a stem cell transplant works in treating patients with multiple myeloma. Chemotherapy drugs, such as melphalan, are given to prepare the bone marrow for the stem cell transplant. Giving colony-stimulating factors, such as XMO2 Filgrastim (Granix), may help multiple myeloma cells move from the patient's bone marrow to the blood where they may be more sensitive to treatment with melphalan. It is not yet known whether adding XMO2 Filgrastim (Granix) to melphalan before a stem cell transplant will work better than melphalan alone in treating multiple myeloma
Interventions
- PROCEDURE Autologous Stem Cell Transplant (ASCT)
- DRUG Granix
- DRUG High dose melphalan (HDR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2015-01-20 |
| Est. Completion | 2019-09-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02112045
The ClinicalTrials.gov registry entry for NCT02112045 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Autologous Stem Cell Transplant (ASCT) is the first listed.
NCT02112045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02112045 about?
NCT02112045 is a clinical study titled "A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation". This randomized phase II trial compares how well adding XMO2 Filgrastim (Granix) to melphalan before a stem cell transplant works in treating patients with multiple myeloma. Chemotherapy drugs, such as melphalan, are given to prepare the bone marrow for the stem cell transplant. Giving colony-stimul...
What is the current status of trial NCT02112045?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2015-01-20. Estimated completion is 2019-09-10.
What interventions are being tested in trial NCT02112045?
The interventions under investigation include: Autologous Stem Cell Transplant (ASCT) (PROCEDURE), Granix (DRUG), High dose melphalan (HDR) (DRUG).
Who is sponsoring clinical trial NCT02112045?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.